Company: CSTL
Filing Date: 2025-03-28
Form Type: PRE 14A
Source: 0001447362-25-000050
Chunk: 57

Company: CASTLE BIOSCIENCES INC
Filing Date: 2025-03-28
Form: PRE 14A
Chunk 57
---
, Inc. (IRTC) |     | uOraSure Technologies, Inc. (OSUR) |     | uTwist Bioscience Corporation (TWST)            |     |                        |

Changes from Prior Peer Group (1)

| Added for 2024                 |     | Removed for 2024              |
| ADMA Biologics, Inc.           |     | Codexis, Inc.                 |
| BioCryst Pharmaceuticals, Inc. |     | NanoString Technologies, Inc. |
| Mesa Laboratories, Inc.        |     | Shockwave Medical, Inc.       |

(1) Primarily due to change in revenue, market value, and/or being acquired.

#### 56Castle Biosciences 2025 Proxy Statement

#### Compensation Discussion and Analysis

### ELEMENTS OF OUR EXECUTIVE COMPENSATION PROGRAM
To maintain a competitive and comprehensive overall compensation package, we utilize three primary compensation elements to reward our executives: base salary, short-term annual cash bonuses, and long-term equity compensation. When setting our compensation program, we focus on motivating our executive officers to lead our entire organization toward achieving both short-term and long-term strategic, financial and operational goals, and increasing stockholder value, without encouraging excessive risk-taking.

#### Base Salaries
Base salaries serve to provide fixed cash compensation to our executive officers for performing their ongoing responsibilities. Base salaries for our executive officers are approved by the Compensation Committee upon employment, and are reviewed and adjusted, as appropriate, by the Compensation Committee on an annual basis, based on consideration of various factors, including:

• The individual’s role and responsibilities;

• Individual contribution and performance over the past year;

• Labor market conditions;

• Inflation;

• Corporate performance; and

• Salaries for similar positions within our industry and peer group.

Our Compensation Committee and, with respect to our CEO, the independent members of the Board, approved the following base salary for our NEOs for fiscal 2024. The below increases were in line with the general policies implemented across the Company in setting pay increases.

| Named Executive Officer |     |         | 2023 Base Salary 
 ($)              |     |         | 2024 Base Salary 
 ($)              | Change 
 (%)    |     |   |
| Derek J. Maetzold       |     | 686,400 |                  |     | 715,572 |                  |        | 4.3 | % |
| Frank Stokes            |     | 488,800 |                  |